ArticleBiologics : targets & therapy2026

Net Present Value Impact of FDA's Phase 3 Waivers on Monoclonal Antibody Biosimilar Development.

Ranjit Ranbhor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.